Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03208413
Other study ID # 2017001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 19, 2017
Est. completion date July 30, 2020

Study information

Verified date November 2019
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Yamei Tang, M.D., Ph.D.
Phone 86-13556001992
Email yameitang@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in radiation-induced brain injury.

Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University / Yameitang.

Primary outcome measure: The primary endpoint is the brain injury remission at week 15. In brief, the brain lesion will be evaluated by using brain MRI scan before and after thalidomide regimen. The clinical efficacy is defined as ≥ 25% reduction in brain edema volume on FLAIR images at week 15, as compared with that before thalidomide usage.


Description:

There is no acknowledged and effective standard treatment for radiation-induced brain injury (RI). Glucocorticoids and bevacizumab during acute period are optional ways to reduce the brain edema. However, glucocorticoids and bevacizumab are unsuitable or ineffective for some patients, especially in the early stage of RI. The investigators supposed that angiogenesis might play a key role in the pathogenesis of RI, and that thalidomide, as an antiangiogenic drug, would reduce immature angiogenesis and improve vessel maturation in RI.

Primary objectives: This phase II clinical trial aims to evaluate the indications, therapeutic effects and safety of thalidomide in radiation-induced brain injury.

OUTLINE: This is a phase II, open-label, single arm clinical trial. Patients are enrolled and administrated with thalidomide. Thalidomide is supplied as 25 mg per pill to be taken by mouth.

Arm І: Patients receive thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date July 30, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers No
Gender All
Age group 35 Years and older
Eligibility Inclusion Criteria

- Prior irradiation >/= 12 months prior to study entry.

- Radiographic evidence to support the diagnosis of radiation-induced brain injury without tumor recurrence.

- Age>/= 35 years.

- Contraindication to glucocorticoids and bevacizumab treatment due to history or high risk of severe adverse effects, or non-effective response to glucocorticoids and bevacizumab treatment in 12 months prior to study entry.

- Estimated life expectancy must be greater than 12 months.

- Routine laboratory studies: bilirubin </=1.0 * upper limits of normal (ULN); aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT)< 1.0 * ULN; creatinine <1.0 * ULN; white-cell count >/= 4,000 per cubic millimeter; neutrophils count >/=1500 per cubic millimeter platelets >/= 100,000 per cubic millimeter; Hb >/=110 gram per millilitres; PT, APTT, INR in a normal range.

- Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document.

Exclusion Criteria

- Evidence of tumor metastasis, recurrence, or invasion;

- Current usage of bevacizumab;

- Current usage of glucocorticoids;

- Evidence of very high intracranial pressure that suggests brain hernia and need surgery;

- History of psychiatric diseases before radiotherapy;

- History of seizures;

- History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial infaction, unstable angina, within 6 months;

- New York Heart Association Grade II or greater congestive heart failure;

- Serious and inadequately controlled cardiac arrhythmia;

- Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic aneurysm, history of aortic dissection;

- Severe infection;

- History of allergy to relevant drugs;

- Pregnancy, lactation, or fertility program in the following 12 months;

- History or current diagnosis of peripheral nerve disease;

- Abnormal in liver and renal function;

- Active tuberculosis;

- Transplanted organs;

- Human immunodeficiency virus;

- Participation in other experimental studies.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Thalidomide
Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.

Locations

Country Name City State
China Cancer canter of Sun Yat-sen University Guangzhou Guangdong
China Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou Guangdong
China Guangzhou Huiai Hospital Guanzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the brain injury remission The brain injury remission is defined as = 25% reduction in brain edema volume on FLAIR images at week 15, as compared with that before thalidomide usage Week 15
Secondary improvement of quality of life the difference value of WHO-QOL scale before and after thalidomide regimen Week 15
Secondary improvement of neurological function the difference value of LENT/SOMA scales before and after thalidomide regimen Week 15
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Completed NCT02985164 - Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography Phase 3
Recruiting NCT04152681 - Effect and Safety of Apatinib on Radiation-Induced Brain Injury Phase 2
Recruiting NCT04818099 - Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy Phase 3
Completed NCT03667859 - Vaginal Elasticity Assessment Before and After Brachytherapy/Pelvic Radiation
Terminated NCT03660618 - LSFG-SKIN, Laser Speckle Flowgraphy N/A
Completed NCT00725244 - Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias Phase 4
Completed NCT00001523 - Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation N/A
Recruiting NCT03907371 - The Effect of Donepezil in Radiotherapy-related Cognitive Impairment. Phase 2
Not yet recruiting NCT05063773 - Novel Wireless Mixed Reality Headset for Image Guidance in Cardiac Catheterization Laboratory N/A
Completed NCT00001437 - Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis Phase 2
Recruiting NCT06325982 - Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury N/A
Completed NCT02972736 - RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study
Completed NCT02104271 - Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. Phase 2
Terminated NCT00134628 - Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries Phase 3
Completed NCT03961217 - Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes